In Q3 2025, Perceptive Advisors held 83 positions worth $3.2B. They initiated 9 new positions and exited 99. Their largest holding was RYTM ($246.3M). Portfolio value grew +22.2% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q3 2025?
Perceptive Advisors held 83 biotech stocks in their 13F portfolio in Q3 2025. Their top positions include RYTM, ASND, ACLX, CELC, NUVL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q3 2025?
Perceptive Advisors's tracked biotech portfolio was worth $3.2B across 83 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q3 2025?
Perceptive Advisors initiated 9 new positions in Q3 2025, including AAVXF, KOD, GOSS, KRYS, HTFL and 4 more. They also increased 34 existing positions.
What did Perceptive Advisors sell in Q3 2025?
Perceptive Advisors fully exited 99 positions in Q3 2025, including TRAW, PCVX, NTRA, NAMSW, CBAY and 94 more. They also trimmed 20 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisorsportfolio →